BioCentury
ARTICLE | Company News

Menarini, Vivus sales and marketing update

May 19, 2014 7:00 AM UTC

In its 1Q14 earnings, Vivus disclosed that Menarini launched Spedra avanafil for erectile dysfunction in France, Germany, Italy and the U.K. in March and in Spain in April. The March launches triggered milestone payments of €3 million ($4.1 million) for each country to Vivus, or €12 million ($16.5 million) in total, under a 2013 deal granting Menarini commercialization rights in over 40 European countries, plus Australia and New Zealand. The launch in Spain triggered the fifth and final milestone payment to Vivus of €3 million. Menarini declined to disclose financial terms, including pricing information for the countries (see BioCentury, July 22, 2013). ...